Suchergebnisse - "Mader, Robert M"

PubPharm (176)

1

Circulating microRNAs and cardiomyocyte proliferation in heart failure patients related to 10 years survival

enthalten in: ESC heart failure | 2023

von Wagh, V. | Nguemo, F. | Kiseleva, Z. | +3

2

Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer

enthalten in: Journal of personalized medicine | 2023

von Bartl, T. | Grimm, C. | Mader, R. | +4

3

Signs and signals limiting myocardial damage using PICSO : a scoping review decoding paradigm shifts toward a new encounter

enthalten in: Frontiers in cardiovascular medicine | 2023

von Mohl, W. | Kiseleva, Z. | Jusic, A. | +2

4

Precision Medicine in Inflammatory Bowel Diseases : Challenges and Considerations for the Path Forward

enthalten in: Gastroenterology | 2022

von Ricciuto, A. | Rauter, I. | McGovern, D. | +2

5

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

enthalten in: Cancers | 2022

von Taghizadeh, H. | Maj-Hes, A. | Prager, G. | +2

6

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

enthalten in: European journal of clinical pharmacology | 2021

von Zeitlinger, M. | Bauer, M. | Reindl-Schwaighofer, R. | +14

7

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo

enthalten in: Chemical science | 2021

von Schueffl, H. | Theiner, S. | Hermann, G. | +16

8

Tissue distribution of epirubicin after severe extravasation in humans

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Nedomansky, J. | Haslik, W. | Pluschnig, U. | +6

9

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

enthalten in: European journal of clinical pharmacology | 2021

von Zeitlinger, M. | Bauer, M. | Reindl-Schwaighofer, R. | +14

10

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

enthalten in: European journal of clinical pharmacology | 2021

von Zeitlinger, M. | Bauer, M. | Reindl-Schwaighofer, R. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]